Back to Journals Drug Design, Development and Therapy Volume 20 GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation Received 1 April 2026 Accepted for publication 2 June 2026 Published 12 June 2026 Volume 2026:20 613616 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Professor Anastasios Lymperopoulos Pengpeng Li, Yangyang Gao, Wei Liu Department of Neurosurgery, Xian Aerospace Hospital of Northwest University, Xian, Shanxi, 710000, Peoples Republic of China Correspondence: Pengpeng Li, Email [email protected] Wei Liu, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity
We offer weight loss injections and weight management programs that incorporate prescription appetite-suppressants or GLP-1s
doi: 10.1093/clinids/19.3.448 499 LoebelMEckeyMSotznyFHahnEBauerSGrabowskiPet al
Step-by-step reconstitution process Following a systematic process ensures consistent results every time
The PA adjuvants are difficult to mass production and of high cost
After the medication is compounded at the pharmacy, it is shelf stable for 90 days
